Index

Figures are indicated by italic page numbers, Tables by bold numbers.

ABIS (All Babies in Southeast Sweden) cohort study, 96
ACIP see Advisory Committee on Immunization Practices
ACR see American College of Rheumatology
acrodynia, and mercury exposure, 59
acute disseminated encephalomyelitis (ADEM), 2, 49, 130, 136, 137, 311–24
clinical features, 313
definition, 311
diagnostic characteristics, 311–12
diagnostic criteria, 313
differentiation from MS, 311–12, 314, 316
differentiation from viral encephalitis, 314
epidemiology, 312
genetic predisposition, 314
and HBV vaccine, 49
and HPV vaccine, 49, 165, 170
hyperacute form, 316
iatrogenic cases, 314
immunological mechanisms, 315
and influenza vaccine, 181
lesions, 315–16
and MMR vaccine, 130
multiphasic (MADEM), 311, 312
neurologic symptoms, 313
neuropathology, 315–16
paraclinical tests, 313
pathogenesis, 313–15
post-vaccination ADEM, incidence, 312, 317, 324
lesions, 316
prognosis, 316–17
recurrent (RADEM), 311, 312
treatment of, 316
and yellow fever vaccine, 136, 137
adapter proteins, 15
adaptive immune response and adjuvants, 14
regulation of, 28
adenovirus infections, and celiac disease, 303
adjuvant effect, 2, 26–30, 214, 224, 262
adjuvant-induced arthritis (AIA), 234
adjuvant-related diseases, 17–19, 88, 218
adjuvency mechanisms, 14–17
adjuvants, 2, 147–8
adverse effects, 20, 148, 251, 264–5, 315
modes of action, 14
new-generation products, 267
role of, 2, 11, 103, 214, 261, 314–15
types, 11–13, 215–16, 219
see also autoimmune/inflammatory syndrome induced by adjuvants (ASIA)
Advax [adjuvant], 11, 12
adverse effects of adjuvants, 20
mechanisms, 15–17, 147–8
adverse events/reactions, 1, 25
susceptibility factors, 3, 6
Advisory Committee on Immunization Practices (ACIP) recommendations influenza vaccination, 238, 307–8
live vaccines for immunosuppressed patients, 236, 242
meningococcal vaccination, 187
pneumococcal vaccination, 192, 237, 241
allergic reactions, 50, 80
and BCG, 199
see also food allergies alopeia, and HBV vaccination, 150
alopecia areata (AA), 255
clinical manifestations, 255–6
environmental factors, 256–7
epidemiology, 255
genetic factors, 256
infectious agents affecting, 256–7
pathogenesis, 256–7
vaccination-induced, 257
alum particles as lysosome-destabilizing adjuvants, 261–3, 315
systemic diffusion of, 265–6
take up by macrophages, 47, 262, 265
see also aluminum hydroxide/salts accumulation in brain, 48, 266
allergic and autoimmune effects, 57, 60–1, 234
bioavailability, 44
body burden, 50
clearance half-life, 46
dietary intake vs vaccine-derived, 45–7
and neurological diseases, 44
neurotoxicity, 44, 167, 235, 265, 267
quantities in various vaccines, 216
sensitization to, 50
susceptibility to adverse reaction, 50
aluminum hydroxide/salts [adjuvants], 2, 11, 20, 148, 216, 261–2
adjuvant effect, 15, 16, 26, 262
autoimmune effects, 18, 19, 114, 143, 153, 167, 168, 303
animal models, 35, 36, 94
biopersistence, 47–8, 263–4, 346
MMF lesion as biomarker, 264
blood–brain/blood–CSF barrier crossed by, 43, 46, 48, 266
complexes formed with other vaccine ingredients, 46, 168
in diphtheria vaccines, 4, 49, 167
excretion from body, 46
in HBV vaccine, 4, 49, 148, 153
in HPV vaccines, 4, 163, 167, 168
innate immune responses induced by, 43, 262
licensing/regulation of, 45
long-term persistence in body, 47–8, 263–4
long-term safety, 267
lysosomal functions disrupted by, 261–3, 315
in pneumococcal vaccine, 5, 20, 191, 195
proposed withdrawal from vaccines, 267
safety limits in vaccines, 45
in tetanus vaccines, 4, 5, 49, 167
see also alum particles
Advisory Committee on Immunization Practices (ACIP) recommendations influenza vaccination, 238, 307–8
live vaccines for immunosuppressed patients, 236, 242
meningococcal vaccination, 187
pneumococcal vaccination, 192, 237, 241
allergic reactions, 50, 80
and BCG, 199
see also food allergies
alum particles as lysosome-destabilizing adjuvants, 261–3, 315
systemic diffusion of, 265–6
take up by macrophages, 47, 262, 265
see also aluminum hydroxide/salts accumulation in brain, 48, 266
allergic and autoimmune effects, 57, 60–1, 234
bioavailability, 44
body burden, 50
clearance half-life, 46
dietary intake vs vaccine-derived, 45–7
and neurological diseases, 44
neurotoxicity, 44, 167, 235, 265, 267
quantities in various vaccines, 216
sensitization to, 50
susceptibility to adverse reaction, 50
aluminum hydroxide/salts [adjuvants], 2, 11, 20, 148, 216, 261–2
adjuvant effect, 15, 16, 26, 262
autoimmune effects, 18, 19, 114, 143, 153, 167, 168, 303
animal models, 35, 36, 94
biopersistence, 47–8, 263–4, 346
MMF lesion as biomarker, 264
blood–brain/blood–CSF barrier crossed by, 43, 46, 48, 266
complexes formed with other vaccine ingredients, 46, 168
in diphtheria vaccines, 4, 49, 167
excretion from body, 46
in HBV vaccine, 4, 49, 148, 153
in HPV vaccines, 4, 163, 167, 168
innate immune responses induced by, 43, 262
licensing/regulation of, 45
long-term persistence in body, 47–8, 263–4
long-term safety, 267
lysosomal functions disrupted by, 261–3, 315
in pneumococcal vaccine, 5, 20, 191, 195
proposed withdrawal from vaccines, 267
safety limits in vaccines, 45
in tetanus vaccines, 4, 5, 49, 167
see also alum particles
Aluminum accumulation in brain, 48, 266
allergic and autoimmune effects, 57, 60–1, 234
bioavailability, 44
body burden, 50
clearance half-life, 46
dietary intake vs vaccine-derived, 45–7
and neurological diseases, 44
neurotoxicity, 44, 167, 235, 265, 267
quantities in various vaccines, 216
sensitization to, 50
susceptibility to adverse reaction, 50
aluminum hydroxide/salts [adjuvants], 2, 11, 20, 148, 216, 261–2
adjuvant effect, 15, 16, 26, 262
autoimmune effects, 18, 19, 114, 143, 153, 167, 168, 303
animal models, 35, 36, 94
biopersistence, 47–8, 263–4, 346
MMF lesion as biomarker, 264
blood–brain/blood–CSF barrier crossed by, 43, 46, 48, 266
complexes formed with other vaccine ingredients, 46, 168
in diphtheria vaccines, 4, 49, 167
excretion from body, 46
in HBV vaccine, 4, 49, 148, 153
in HPV vaccines, 4, 163, 167, 168
innate immune responses induced by, 43, 262
licensing/regulation of, 45
long-term persistence in body, 47–8, 263–4
long-term safety, 267
lysosomal functions disrupted by, 261–3, 315
in pneumococcal vaccine, 5, 20, 191, 195
proposed withdrawal from vaccines, 267
safety limits in vaccines, 45
in tetanus vaccines, 4, 5, 49, 167
see also alum particles
Index

aluminum overload, CFS induced by, 346
Alzheimer's disease (AD), 44, 49, 60
American College of Rheumatology (ACR), vaccination advice for
ARD/ARD patients, 236, 237, 238, 240, 241, 242
antiphospholipid syndrome (APS), 44
anaphylactoid purpura, and intravesical
BCG therapy, 203
anthrax vaccine
adjuvants in, 261, 266
and Gulf War syndrome, 19, 266
resultant autoimmune diseases, 228, 284, 286, 321, 323, 341, 351, 352
"antigen presentation", 14, 70
antigen-carrier systems, 12
antigen-mediated infections, detection by
TLRs, 15
antigen-presenting cells (APCs), 26, 67, 272
activation of, 179, 227, 234
alum particles taken up by, 47
antigen-specific recognition of
pathogens, 25–6
antimyelin antibodies, in children with
ADEM, 314
antineutrophil cytoplasmic antibodies
(ANCA)-associated vasculitides, 98, 227, 228
antigenicemic syndrome (APS), 141
antibodies in, 141
clinical associations, 154
and HBV infection/vaccination, 149, 154
collagen-induced, 36, 37, 234
CFA-induced, 36, 37, 234
and BCG immunotherapy, 201, 202
collagen-induced, 36, 37, 234
and HBV vaccination, 149, 154
and MMR vaccination, 131
see also reactive arthritis; rheumatoid
arthritis
AS01 [adjuvant], 20
AS02 [adjuvant], 12, 20
AS03 [adjuvant], 11, 20, 294, 295
mechanism of action, 297
compared with MF59, 297
AS04 [adjuvant], 12, 20, 163
AS15 [adjuvant], 20
ASIA see main entry:
autoimmune/inflammatory
syndrome induced by adjuvants
ASIA registry, 103–5
analyses and uses of data, 104
limitations, 104
purpose, 104
structure, 104
asthma, and BCG, 199
attenuated [live] vaccines see
live-attenuated vaccines
autism spectrum disorders, 44, 50
autoantibodies, 18, 81, 93–102
vaccine-induced, 93–102, 175
in animals, 93–5
in healthy people, 95–6
in patients with autoimmune
diseases, 96–100
autoantigen-specific responses, 25
autoimmune bullous disorders, 337
diagnosis, 337
epidemiology, 337–8
pathogenesis, 338–40
and vaccination, 340–1
see also Bullous pemphigoid; pemphigus vulgaris
autoimmune diseases
environmental triggers, 1, 17, 339
experimental models, 17, 18, 26,
35–9
genetic basis, 1, 25
patients, vaccination of, 96–100,
107–26, 138–9
slow evolution before clinical onset,
169–71
vaccination-induced, 2, 257
autoimmune hemolytic anemia, and
diseases, 96–100
autoimmune hepatitis (AIH),
post-vaccinal development, 138,
166, 167
autoimmune inflammatory rheumatic
diseases (AIRDs) patients
risk of infection, 113–14
herpes zoster infection, 114, 242
influenza infection, 113, 177, 241
pneumococcal infection, 114, 191,
237, 241
tuberculosis, 107, 114, 242
safety and efficacy of vaccines,
114–20
diphtheria–tetanus [and DTP]
vaccines, 120, 240
HBV vaccine, 117–19, 121, 122, 238, 241–2
HPV vaccine, 119–20, 121, 122
influenza vaccine, 96–7, 114–17,
121, 122, 238, 241
MMR vaccine, 236
pneumococcal vaccine, 117, 121, 122, 193, 237, 241
tetanus toxoid vaccine, 120, 121, 122, 237, 240
varicella vaccine, 238, 242
yellow fever vaccine, 138–9
see also rheumatoid arthritis; Sjögren's
syndrome; systemic lupus
erythematosus; systemic
sclerosis
autoimmune thyroiditis, 35, 37, 60
see also Hashimoto's thyroiditis
autoimmune bullous disorders, see also
bullous pemphigoid, pemphigus vulgaris
bacillus Calmette–Guérin see BCG
tuberculosis triggers, 1, 25
BALB/c mice, 18, 36, 37, 94, 142, 143
BCG, 197
autoimmune responses, 200–4, 213
intradermal BCG, 201
"bridging symptoms" [nonspecific
ASYA symptoms], 3, 170
comparison with UCTD, 251, 252
conditions incorporated in, 19, 79,
83, 87, 89, 215, 251, 266, 276,
334
diagnostic criteria, 88, 89, 215
registry, 103–5
symptoms, 2–3, 19, 50–1, 89, 169,
266, 334
see also Gulf War syndrome;
microphagic myofascitides;
post-vaccination phenomena;
sick building syndrome;
silicosis
autoimmune neuropathies
and HBV vaccine, 149, 151–4, 170
and HPV vaccine, 165, 167
and MMR vaccine, 130
slow evolution before clinical onset,
170
and yellow fever vaccine, 137–8
autoimmune rheumatic disease (ARD)
patients
herpes zoster infection, 107
influenza infection, 177, 241
respiratory infections, 109, 241
tuberculous infection, 107, 242
vaccination using inactivated
vaccines, 108–10
diphtheria–tetanus–pertussis
vaccine, 109
diphtheria–tetanus vaccine, 110
IBV vaccine, 110
HBV vaccine, 110, 149–50, 154–5
HPV vaccine, 110
influenza vaccine, 109–10
meningooccal vaccine, 110, 189
pneumococcal vaccine, 109, 193,
237, 241
tetanus toxoid vaccine, 110, 240
vaccination using live vaccines,
107–8
BCG vaccine, 107, 238, 242
herpes zoster/varicella vaccine, 107–8,
238, 242
MMR vaccine, 108, 236
yellow fever (YF) vaccine, 108,
138–9, 240
see also rheumatoid arthritis; Sjögren's
syndrome; systemic lupus
erythematosus; systemic
sclerosis
autoimmune thyroiditis, 35, 37, 60
see also Hashimoto's thyroiditis
autoimmunity bullous disorders, see also
bullous pemphigoid, pemphigus vulgaris
"antigen presentation", 14, 70
antigen-carrier systems, 12
antigen-mediated infections, detection by
TLRs, 15
antigen-presenting cells (APCs), 26, 67, 272
activation of, 179, 227, 234
alum particles taken up by, 47
antigen-specific recognition of
pathogens, 25–6
antimyelin antibodies, in children with
ADEM, 314
antineutrophil cytoplasmic antibodies
(ANCA)-associated vasculitides,
98, 227, 228
antigeneric syndrome (APS), 141
antibodies in, 141
clinical associations, 154
and HBV infection/vaccination, 144,
150, 154–5
and influenza vaccine, 144–5
and IFN, 272
serological marker, 154
and tetanus toxoid vaccine, 141–4,
168, 212–13
antineutrophil antibodies, 81
Arepanrix [H1N1 influenza] vaccine,
295, 296
arthritis
and BCG immunotherapy, 201, 202
CFA-induced, 36, 37, 234
chronic, 17, 18, 36
collagen-induced, 36, 37, 234
and HBV vaccination, 149, 154
and MMR vaccination, 131
see also reactive arthritis; rheumatoid
arthritis
AS01 [adjuvant], 20
AS02 [adjuvant], 12, 20
AS03 [adjuvant], 11, 20, 294, 295
mechanism of action, 297
compared with MF59, 297
AS04 [adjuvant], 12, 20, 163
AS15 [adjuvant], 20
ASIA see main entry:
autoimmune/inflammatory
syndrome induced by adjuvants
ASIA registry, 103–5
analyses and uses of data, 104
limitations, 104
purpose, 104
bystander activation mechanism, 147, 177, 179, 216, 224, 227, 276, 283, 297, 298, 302

C57BL/6 mice, 36, 37, 143
cadmium, 57, 59
gCampylobacter jejuni infections, and celiac disease, 303

cancer treatments, 20, 30, 197, 200

Cantigrp [H1N1 influenza] vaccine, 286, 295
case series reports, 103
cataplexy see narcolepsy with cataplexy
celiac disease (CD), 301–4

associations with infection, 302, 302 diagnosis, 301

environmental factors, 301

gene factors, 1, 302

hookworm as therapeutic strategy, 302

and infectious agents, 302, 303–4
celiac disease patients, incidence of type 1 diabetes, 304
celiac peptide, 303
cell-surface receptor genes, 74

Celtura [H1N1 influenza] vaccine, 286, 295

Celvapan [H1N1 influenza] vaccine, 286, 295

Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP), recommendations, 187, 192, 236, 237, 238, 241, 242

central nervous system (CNS) involvement

HBV vaccination, 152–3

HPV vaccination, 170

inflammatory demyelination, 170

MMR infection/vaccination, 130
tetanus vaccination, 143

yellow fever vaccination, 187

CFS patients

involvement

in chronic fatigue syndrome, 346

and exposure to HBV vaccine and silicone, 333, 346

and HBV vaccine, 149, 153–4, 250, 333, 346

metal-induced, 59, 60, 61

possible causes, 346

silicone-induced, 80–1, 83, 333, 346

symptoms, 345

and vaccinations, 333, 346–7
cigarette smoke, metals in, 58
clinically isolated syndrome (CIS), 165, 311–12

“cold vaccine”, dermamyositis developed after, 353

Coley, William, 30

collagen antibodies, 81

collagen-induced autoimmune diseases, 36, 37, 218, 234

complement dysfunction patients, 248

meningooccal vaccination, 187

complete Freund’s adjuvant (CFA), 11, 15

use in animal models, 26, 28, 29, 36, 37, 94, 143, 234, 314

conditioned pain modulation (CPM), 331

conjugated vaccines, 67

connective-tissue diseases (CTDs)

autoantibody reactivities, 248

clinical manifestations, 248

and siliconosis, 18, 80, 81–2, 87, 88

see also mixed connective-tissue diseases;

undefined/undifferentiated connective-tissue diseases

Coxsackievirus infection, autoimmune reaction to, 25, 28–9

CPR7909 [adjuvant], 12

cryoglobulinemia, and HCV virus, 224

cystic fibrosis vaccine, 20

cytokine genes, 73–4

cytomegalovirus (CMV) infection and celiac disease, 303

and chronic fatigue syndrome, 346

and ITP, 271, 274, 279

Dark Agouti (DA) rats, 35–6, 37
dehydroxylation, animal model for, 35, 37

delayed-type hypersensitivity adjuvant-induced, 80, 224

and BCG vaccination, 201

metal-induced, 57–8, 60, 80

demyelinating CNS disorders and hepatitis B vaccine, 303

post-vaccinal symptoms, 2–3

Index

361
dem yminating CNS disorders (continued)
see also acute disseminated encephalomyelitis, multiple sclerosis

demyinating diseases
and HPV vaccine, 49, 165, 167
and pneumococcal vaccine, 194
dental amalgam, 58, 59, 60
dermal vasculitis with panuveitis, 228
dermatomyositis (DM), 350–1
dermatomyositis patients,
influenza vaccination, 116
dermis, 337
diabetes, type 1 (T1D)
and vaccination
role of infections in pathogenesis, 284
and vaccination
in children, 284–6
in adults, 286
in children, 284
and BCG vaccination, 201
and ME/CFS, 265
and ASIA criteria, 251
and PMR,
clinical overlap with chronic fatigue syndrome, 254

diphtheria–tetanus–acellular-pertussis (DTaP) vaccine, 352–3
diphtheria–tetanus–polio (DT–IPV) vaccine, 352
and silicone gel-filled implants, 83, 89


dogs, post-vaccination autoantibody production in, 93–4, 216
Down’s syndrome patients, alopecia, 256
egg protein [ovalbumin], as vaccine ingredient, 4, 5, 224
encephalitis
vaccine-induced, 130, 132, 303, 352
see also Japanese encephalitis;
tick-borne encephalitis
environmental triggers [of autoimmune diseases], 1, 17, 256
eosinophilic granulomatosis with polyangiitis (EGPA), 227, 228
epidemiology, and vaccine response, 68–9
erdimeris, 337
Epstein–Barr virus (EBV) infection
and alopecia, 256
and celiac disease, 303
and chronic fatigue syndrome, 346
innate immunity triggered by, 199
and ITP, 271, 274, 279
and pemphigus vulgaris, 340
erythema multiforme, and HBV vaccination, 150, 155
ethylmercury, 37, 38, 59
European League Against Rheumatism (EULAR), recommendations for immunizations in AIRD/ARD patients, 108–9, 114, 117, 120–2, 177–8, 193, 204, 235–6, 237, 238, 240, 241, 242
epilepsy
experimental autoimmune encephalomyelitis (EAE), 26, 49, 313, 314
experimental autoimmune encephalomyelitis grave
(EAMG), 17
experimental autoimmune myocarditis (EAM), 26, 28
experimental autoimmune uveitis (EAU), 26
experimental models of adjuvant-induced autoimmune effects, 17, 18, 26, 35–9, 49, 90, 313–14
murine models, 18, 35–6, 37, 90
primates, 37, 38–9
rabbits, 37, 38
salmon, 36–8, 37
swine, 37, 38
fibromyalgia/fibromyalgia syndrome
(FM/FMS), 331
and ASIA criteria, 251
clinical overlap with chronic fatigue syndrome, 251, 333, 345
FM/FMS patients
HPV vaccination, 165
influenza vaccination, 116–17
metal hypersensitivity, 60
and ME/CFS, 263
metal-induced, 60
and MEF, 264
and MMF, 264
and rubella vaccine, 332

Index
Graves’ disease, and HBV vaccine, 150, 155
Guillain–Barre syndrome (GBS), 2
and HI1N influenza vaccine, 178, 180, 223, 275, 286
and HBV vaccine, 48, 49, 149
and HPV vaccine, 49, 167, 170
and influenza vaccine, 178, 303
and meningococcal vaccine, 186–7
and MMR vaccine, 130
and pneumococcal vaccine, 194
and swine flu vaccine, 148, 178, 180, 223, 283
and yellow fever vaccine, 116, 137, 286
Gulf War syndrome (GWS), 149
adjuvant involvement, 18, 19, 35, 215, 234
antisqualene antibodies, 35, 333
as ASIA condition, 19, 79, 215, 251, 266, 276, 334
and FMS/CFPS, 332
and PTSD, 332
and vaccination, 19, 266, 332–3
HI1N influenza A virus
2009 pandemic, 176
clinical symptoms, 176
disease severity biomarker, 176
host immune response, 176
immunomodulatory agents, 177
pneumonia, 176–7
pregnant patients, 177
HI1N influenza A virus infection, and ITP, 274
HI1N influenza A virus vaccine
adjuvants in, 30, 178, 294, 295, 296–7
AIRD/ARD patients, 110, 121, 239
autoantibodies induced by, 95
genetics, 73
ingredients, 4, 216
resultant autoimmune diseases
bullous dermatoses, 340
diabetes, 284, 285
Hashimoto’s disease patients, diphtheria and tetanus vaccination, 120
Hashimoto’s thyroiditis, 47, 61
Helicobacter pylori infection
and bullous dermatoses, 339
and celiac disease, 303
and ITP, 273
Hemoch–Schönlein purpura (HSP) and HBV vaccine, 149, 155, 227
and influenza vaccine, 179, 227
and intravenous BCG therapy, 203
and meningococcal vaccines, 187, 227
hepatitis A virus (HAV) vaccine
adjuvants in, 20, 216
AIRD/ARD patients, 110, 121
autoantibodies induced by, 95
genetics, 73
ingredients, 4, 216
resultant autoimmune diseases, 2, 49, 227, 271, 317, 320, 323, 354
hepatitis B virus (HBV), 148
transmission routes, 148
virological marker, 148
hepatitis B virus (HBV) infection
and bullous dermatoses, 339
and celiac disease, 303
hepatitis B virus (HBV) vaccine
adjuvants in, 20, 216
AIRD/ARD patients, 110, 121
autoantibodies induced by, 95
genetics, 73
ingredients, 4, 216
resultant autoimmune diseases, 2, 49, 227, 271, 317, 320, 323, 354
hepatitis B virus (HBV), 148
transmission routes, 148
virological marker, 148
hepatitis B virus (HBV) infection
and bullous dermatoses, 339
and celiac disease, 303
hepatitis B virus (HBV) vaccine
adjuvants in, 20, 216
AIRD/ARD patients, 110, 121
autoantibodies induced by, 95
genetics, 73
ingredients, 4, 216
resultant autoimmune diseases, 2, 49, 148, 151, 153
AIRD/ARD patients, 110, 17–19, 121, 122, 238, 241–2
ASIA symptoms induced by, 334
autoantibodies induced by, 95
genetics, 72, 73, 74
heritability studies, 69
ingredients, 4, 20, 148, 151, 216
protection efficiency, 67, 68
resultant autoimmune diseases, 2, 3, 48, 49
ADEM, 317, 319–20, 323
alopecia, 257
APS, 144, 150, 154–5
arthritis, 149, 154, 303
autoimmune rheumatoid diseases, 149–50, 154–5
autoimmune skin conditions, 150, 155
bullous dermatoses, 340, 341
CFS and FMS, 333, 346
demyelinating CNS disorders, 303
dermatomyositis, 351, 353
diabetes, 285, 286
GBS, 48, 49, 149, 353
immune-mediated neutonal damage, 48
inflammatory joint disease, 2
Haemophilus influenzae type b (Hib) vaccine
67
AIRD/ARD patients, 110, 121, 239
autoantibodies induced by, 95
combination with meningococcal vaccine, 186
ingredients, 4, 216
resultant autoimmune diseases
bullous dermatoses, 340
diabetes, 284, 285
Hashimoto’s disease patients, diphtheria and tetanus vaccination, 120
Hashimoto’s thyroiditis, 47, 61
HIV vaccine,
herpes zoster vaccine
and celiac disease, 303
and ITP, 271, 274
hepatitis C virus (HCV) vaccine, and celiac disease, 303
herpes zoster infection
AIRD/ARD patients, 114, 242
and alopecia, 237
herpes zoster vaccine
AIRD/ARD patients, 107–8, 121, 238, 242
ingredients, 5
resultant autoimmune diseases, 317, 340, 351
HIV vaccine, 20
HLA class I molecules, antigen processing by, 70–1
HLA class I vaccine effects, 72
HLA class II molecules, antigen processing by, 71–2
HLA class II vaccine effects, 72
HLA haplotypes, 69
 associations, 72–3
HLA region [in human chromosome] class I region, 69, 70
class II region, 69, 70
association with alopecia, 256
class III region, 69, 70
 polymorphism of, 69–73
hookworm, celiac disease treated using, 302
HPV or human papillomavirus
human herpes virus 6 (HPV-6) infection
and chronic fatigue syndrome, 346
and ITP, 274
pemphigus patients, 340
human immunodeficiency virus (HIV) infection, and ITP, 271, 279
Index

363
Index

human leukocyte antigen see HLA
human papillomavirus (HPV), 109
  genetics, 72
human papillomavirus (HPV) infection, 353–4
  and ITP onset, 274
human papillomavirus (HPV) vaccine
  adjuvants in, 20, 46, 163, 216
  adverse reactions, 163–7
  case reports, 164–7
  surveillance data, 163–4, 167
  AIRD/ARD patients, 98, 100, 109–10, 119–20, 121, 122
  ingredients, 4, 20, 46, 163, 216
  manufacturer’s safety data, 167–9
  recommended immunization program, 354
resistant autoimmune diseases, 164–7
AIDs, 49, 165, 167, 170, 321–2, 323
alopecia, 257
autoimmune hepatitis, 166, 167
dermatomyositis, 351, 354
GBS, 167, 170
ITP/thrombocytopenic purpura, 165, 167, 276, 279
MS, 49, 165, 167, 170
polymyositis, 352
possible mechanisms, 171
POTS, 166, 167
primary ovarian failure, 165, 167
SLE, 3, 49, 166, 216, 217
vasculitides, 165, 167, 227
risks vs benefits, 171, 323
safety surveillance programs, 163–5, 167
see also Cervarix; Gardasil
hydrocarbon-based adjuvants, 17, 94, 178, 215
hypersensitivity
  adjuvant-induced, 80, 224
  metal-induced, 57–8, 60, 80, 265
  hypersensitivity diseases, and BCG, 199, 201, 202–3
  hypersensitivity vasculitides (HV), 224, 228
HZ vaccine see herpes zoster vaccine
IC31 [adjuvant], 12
idiopathic inflammatory myopathy (IIM), 349
  clinical manifestations, 350–1
  incidence rate, 349
  see also dermatomylitis; inclusion body myositis; polymyositis
idiopathic interstitial pneumonias (IIPs), 248
idiopathic nonspecific interstitial pneumonia, 248
idiopathic thrombocytopenic purpura
  see immune/idiopathic thrombocytopenic purpura (ITP)
imune response, heterogeneity in, factors influencing, 65, 68
immune response network theory, 75
immune response-related genes
cell-surface receptor genes, 74
cytokine genes, 73–4
HLA region, 69–73
influenza, 75
infectome, associations with celiac disease, 50
inflammasomes, in adjuvant effect, 16, 36, 37, 262
inflammatory gastrointestinal pathologies, 50
inflammatory joint diseases, triggers, 2, 202
inflammatory myopathies and HBV vaccine, 149, 153
  and influenza vaccine, 179
  patients with, and influenza vaccination, 116
influenza, 175
  and immune system, 176–7
  and ITP onset, 274
  and narcolepsy, 293
  patients with underlying conditions, 178
  pregnant patients, 177
“swine flu pandemic” [2009], 176
  see also H1N1 influenza A virus
influenza vaccine, 67
  adjuvants in, 20, 178, 295
  AIRD/ARD patients, 96–8, 98–100, 109, 114–17, 121, 122, 177, 238, 241
autoantibodies induced by, 95, 96–8, 98–100, 175
  and autoimmunity, 178–9
  elderly patients, 178, 179, 293
  first developed, 66
  ingredients, 4
resistant disorders
AIDs, 181, 317, 340, 323
APS, 144–5, 179
bullous dermatoses, 340, 341
chronic fatigue syndrome, 346
GBS, 178, 223, 303
inflammatory myopathy, 179, 353
ITP, 181, 275, 277
JIA, 180
MS, 181
myositis, 351, 352, 353
  narcolepsy, 180
neurological syndromes, 180
PMR, 225, 308, 309
RA, 257
rhabdomyolysis, 353
SLE, 179, 217
Still’s disease, 179–80
vasculitides, 98, 179, 225, 226, 227, 228
  SLE patients, 13, 96, 97, 109, 115–16, 145, 177, 179
  181
  tuftsin-based, 13
  see also swine flu vaccine
innate immune pattern recognition, 26–7
innate immune response and adjuvants, 14, 27–8, 43, 262
  triggering by TLRs, 27, 74
innate related genes, 74
inulin-based adjuvants, 12
invasive pneumococcal disease (IPD), 114, 191
ITP see immune/idiopathic thrombocytopenic purpura
Jenner, Edward, Jr, 26
Japanese encephalitis vaccine, 216, 239, 321
Jenner, Edward, 25, 66
juvenile dermatomyosi
  and HBV vaccine, 149, 153
  patients, influenza vaccination, 116
juvenile idiopathic arthritis (JIA) and influenza vaccine, 180
  JIA patients, effect of vaccinations, 98–100, 235
Kawasaki’s disease (KD), 149, 201, 224, 225
Kawasaki’s disease (KD), 199
Lambert–Eaton myasthenic syndrome (LEMS), 180
leishmaniasis vaccine, 20
leprosy, vaccination against, 199
leukocytoclastic vasculitis (LV), vaccines associated with, 179, 187, 194, 228
lichen planus
and HBV vaccine, 150, 155
and mercury exposure, 59, 60
live-attenuated vaccines, 65, 66, 67
not recommended for
immunosuppressed patients,
108, 121, 178, 204, 209, 236,
238, 239, 240
LT-T-MELISA [metal hypersensitivity
test], 58
lupus see discoid lupus erythematosus;
systemic lupus erythematosus
lupus-like syndromes,
vaccination-induced, 209–14
lupus nephritis, 154, 212
lupus-related autoantibodies, adjuvant
involvement, 18, 36, 94
lyme disease vaccine
resultant autoimmune disease(s),
352, 354
lymphocyte transformation test
(LTT) [for metal hypersensitivity
testing], 58
see also LT-T-MELISA
macrophagic myofasciitis (MMF)
adjuvant involvement, 19, 35, 36, 47,
61, 114, 153, 215, 333, 346
and alum biopersistence, 47, 263–4
as ASIA condition, 19, 79, 215, 251,
266, 276, 334
association with myalgias, 264
chronic fatigue and, 264
clinical manifestations, 47, 61, 263
cognitive alterations in, 264–5
and HBV vaccine, 153, 257
lesions, 47, 61, 263–4
MMF patients, and ME/CFS criteria,
265
pathology, 333
madarosis (eyelash loss), 257
malaria vaccines, 20
ME see myalgic encephalomyelitis
measles infection, and SLE, 213
measles–mumps–rubella (MMR)
vaccine, 67, 351–2
adverse events, 129
AIRD/ARD patients, 108, 214, 236,
237
CNS involvement, 130
developed, 66, 129
genetics, 72–3
ingredients, 5
protection efficacy, 68, 129
resultant autoimmune diseases
arthritis, 257
rheumatoid arthritis, 131
diabetes, 131–2, 285, 286
ITP/thrombocytopenia, 130–1,
148, 223, 271, 276, 277, 278
myositis, 351, 352
reactive arthritis, 303
SLE, 213–14, 218
see also measles vaccine; mumps
vaccine; rubella vaccine
measles–mumps–rubella–varicella
(MMRV) vaccine, 5, 236
measles vaccine, 236, 237
adverse effects, 213–14, 236, 237,
278
genetics, 72, 73, 74
RA patients, 236, 237
resultant autoimmune diseases
AIDEM, 317, 320, 323
diabetes, 284
ITP, 278
Menactra, 5, 186
and GBS, 186–7
meningococcal disease, 185
meningococcal vaccines, 67, 185–6
AIRD/ARD patients, 110, 121, 239
couplet protein/poly saccharide
vaccines, 185–6, 239
immunopathology, 186
ingredients, 5
poly saccharide vaccines, 185, 186,
239
recommendation for persons at risk,
189
resultant diseases
AIDEM, 319, 323
BGS, 186–7
b llous pemphigoid, 187–9, 340
chronic fatigue syndrome, 333
Henoch–Schönlein purpura, 224
myositis, 351, 352, 354
safety studies, 189
types, 186
mercury
allergic and autoimmune effects,
58–60
sources, 58
see also ethyl mercury;
phenyl mercury;
mercury; thimerosal
metal adjuvants, 216, 219
see also aluminum; mercury
metals, immunological effects, 57
phenyl mercury, 37, 38, 58, 59
MF59 [adjuvant], 11, 12, 15, 20,
36, 178, 215
in HIN1 influenza vaccines, 295
compared with AS03-adjuvanted
vaccine, 296–7
mechanism of action, 15, 297
mice models [of adjuvant-induced
autoimmunity], 18, 35–6, 37, 90
see also mice models; rat models
myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS), 265
and fibromyalgia, 265
prevalence, 265
symptoms, 265
see also chronic fatigue syndrome
myalgic patients, MMF in, 264
myasthenia gravis (MG)
expression of autoimmune (EAMG),
17
and HBV vaccine, 149, 153
MG patients, diphtheria and tetanus
vaccination, 120
Mycoplasma infections, and chronic
fatigue syndrome, 346
MyD88 [adapter protein], 15, 27
myelin oligodendrocyte glycoprotein
(MOG), antibodies targeting, 314
myelin proteins, crossreaction with
viral antigens, 314
myelitis
and HBV vaccine, 149, 152–3
and tetanus toxoid vaccine, 143
myocarditis
experimental animal models, 18, 26,
28
virus-induced, 18, 25, 28–9, 148,
352
myopathy, and HBV vaccine, 149,
153
myositis, 349
pathogenesis, 350
vaccine-associated, 350–4
see also dermatomyositis; idiopathic
inflammatory myopathy;
inclusion body myositis;
polymyositis
NALT3 inflammation and, 13
adjuvants, 16, 36, 37, 48–50

Index

Montanide adjuvants, 12, 20, 37, 38
MRI testing, AIDEM diagnosis, 313
multiple sclerosis (MS)
and aluminum exposure, 18, 44, 48,
49, 266
and BCG, 200, 201
differentiation from AIDEM, 311–12,
314
experimental animal model, 49, 313
genetic basis, 1
and HBV vaccine, 48, 49, 148, 149,
152
and MMR vaccine, 49, 165, 167, 170
and mercury exposure, 59, 60
mouse model, 13, 49
MS patients, influenza vaccination,
181
slow evolution before clinical onset,
170
and yellow fever vaccine, 137–8
multiple vaccinations, risks associated
with, 6, 19, 48, 61, 266, 332
mumps vaccine, 236, 237
and diabetes, 284, 285–6
muramyl dipeptide (MDP), 12, 15
murine models [of adjuvant-induced
autoimmunity], 18, 35–6, 37, 90
see also mice models; rat models
myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS), 265
and fibromyalgia, 265
prevalence, 265
symptoms, 265
see also chronic fatigue syndrome
myalgic patients, MMF in, 264
myasthenia gravis (MG)
expression of autoimmune (EAMG),
17
and HBV vaccine, 149, 153
MG patients, diphtheria and tetanus
vaccination, 120
Mycoplasma infections, and chronic
fatigue syndrome, 346
MyD88 [adapter protein], 15, 27
myelin oligodendrocyte glycoprotein
(MOG), antibodies targeting, 314
myelin proteins, crossreaction with
viral antigens, 314
myelitis
and HBV vaccine, 149, 152–3
and tetanus toxoid vaccine, 143
myocarditis
experimental animal models, 18, 26,
28
virus-induced, 18, 25, 28–9, 148,
352
myopathy, and HBV vaccine, 149,
153
myositis, 349
pathogenesis, 350
vaccine-associated, 350–4
see also dermatomyositis; idiopathic
inflammatory myopathy;
inclusion body myositis;
polymyositis
NALT3 inflammation and, 13
adjuvants, 16, 36, 37, 48–50
<table>
<thead>
<tr>
<th>Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>narcolepsy, 291</td>
<td></td>
</tr>
<tr>
<td>environmental factors, 293</td>
<td></td>
</tr>
<tr>
<td>genetic factors, 292–3</td>
<td></td>
</tr>
<tr>
<td>and H1N1 influenza vaccine, 180–1, 294–8</td>
<td></td>
</tr>
<tr>
<td>pathogenesis, 291–2</td>
<td></td>
</tr>
<tr>
<td>narcolepsy with cataplexy, 291</td>
<td></td>
</tr>
<tr>
<td>prevalence, 291</td>
<td></td>
</tr>
<tr>
<td>natural adjuvants, 12–13</td>
<td></td>
</tr>
<tr>
<td>and autoimmunity, 17</td>
<td></td>
</tr>
<tr>
<td>Neisseria meningitidis, 110, 185</td>
<td></td>
</tr>
<tr>
<td>serogroup B (MenB), 186</td>
<td></td>
</tr>
<tr>
<td>vaccination against, 67, 185–6, 239, 346</td>
<td></td>
</tr>
<tr>
<td>see also meningococcal disease</td>
<td></td>
</tr>
<tr>
<td>neomycin [antibiotic], as vaccine ingredient, 4, 5, 224</td>
<td></td>
</tr>
<tr>
<td>neurological diseases</td>
<td></td>
</tr>
<tr>
<td>link to aluminium intake, 44</td>
<td></td>
</tr>
<tr>
<td>and varicella vaccine, 303</td>
<td></td>
</tr>
<tr>
<td>neuromuscular disorders, 12</td>
<td></td>
</tr>
<tr>
<td>HBV-associated, 2, 48, 149, 149, 151–4</td>
<td></td>
</tr>
<tr>
<td>neumyelitis optica and ADEM, 181, 319, 321, 322</td>
<td></td>
</tr>
<tr>
<td>vaccine-affect ed, 49, 194</td>
<td></td>
</tr>
<tr>
<td>see also optic neuritis</td>
<td></td>
</tr>
<tr>
<td>neuropathy, and HBV vaccination, 149, 153, 303</td>
<td></td>
</tr>
<tr>
<td>nickel, allergic and autoimmune effects, 57, 58, 59, 60</td>
<td></td>
</tr>
<tr>
<td>NLRR3 inflammasome, activation by alum, 16, 48–50, 262</td>
<td></td>
</tr>
<tr>
<td>nonspecific interstitial pneumonia (NSIP) patients, 248</td>
<td></td>
</tr>
<tr>
<td>NZB/NZW/F1 mice, 36, 37</td>
<td></td>
</tr>
<tr>
<td>obesity “epidemic”, in US, 284</td>
<td></td>
</tr>
<tr>
<td>oil-based adjuvants, 11, 215–16</td>
<td></td>
</tr>
<tr>
<td>oil-in-water emulsions, in adjuvants, 11, 12, 15, 20</td>
<td></td>
</tr>
<tr>
<td>ophiasis [in alopecia areata], 256</td>
<td></td>
</tr>
<tr>
<td>ophthalmopathy, and intravesical BCG therapy, 203</td>
<td></td>
</tr>
<tr>
<td>optic neuritis</td>
<td></td>
</tr>
<tr>
<td>in ADEM, 312, 313, 317, 321, 322, 323</td>
<td></td>
</tr>
<tr>
<td>and anthrax vaccine, 323</td>
<td></td>
</tr>
<tr>
<td>and BCG, 323</td>
<td></td>
</tr>
<tr>
<td>and DPT vaccine, 49</td>
<td></td>
</tr>
<tr>
<td>and hepatitis A &amp; B vaccines, 49, 323</td>
<td></td>
</tr>
<tr>
<td>and HPV vaccine, 49, 165, 323, 323</td>
<td></td>
</tr>
<tr>
<td>and influenza vaccine, 323</td>
<td></td>
</tr>
<tr>
<td>and measles/MMR/rubella vaccines, 130, 323, 323</td>
<td></td>
</tr>
<tr>
<td>and meningococcal vaccine, 323</td>
<td></td>
</tr>
<tr>
<td>and pneumococcal vaccine, 194, 323</td>
<td></td>
</tr>
<tr>
<td>and varicella, 323</td>
<td></td>
</tr>
<tr>
<td>and tetanus toxoid vaccine, 49, 143</td>
<td></td>
</tr>
<tr>
<td>oral lichen planus, and mercury exposure, 59, 60</td>
<td></td>
</tr>
<tr>
<td>orexin, 291</td>
<td></td>
</tr>
<tr>
<td>and sleep cycle, 292</td>
<td></td>
</tr>
<tr>
<td>orexin neurons, loss of [in narcolepsy], 291, 292, 297</td>
<td></td>
</tr>
<tr>
<td>oxidative damage, and aluminium-mediated, 49</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa vaccine, 20</td>
<td></td>
</tr>
<tr>
<td>pancreatitis, and HPV vaccination, 166, 167</td>
<td></td>
</tr>
<tr>
<td>pancytopenia, and HBV vaccination, 150, 155</td>
<td></td>
</tr>
<tr>
<td>Pandemrix [H1N1 influenza] vaccine, 286, 295</td>
<td></td>
</tr>
<tr>
<td>adjuvant in, 295, 296–7</td>
<td></td>
</tr>
<tr>
<td>and GBS, 180</td>
<td></td>
</tr>
<tr>
<td>and narcolepsy, 180, 294–6</td>
<td></td>
</tr>
<tr>
<td>Panzena [H1N1 influenza] vaccine, 286, 295</td>
<td></td>
</tr>
<tr>
<td>parenteral feeding solutions, limits on aluminium levels, 45</td>
<td></td>
</tr>
<tr>
<td>Parkinsonism dementia, 44</td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease (PD), 49</td>
<td></td>
</tr>
<tr>
<td>parvovirus B19 infection resulting disorders</td>
<td></td>
</tr>
<tr>
<td>chronic fatigue syndrome, 346</td>
<td></td>
</tr>
<tr>
<td>vasculitides, 224</td>
<td></td>
</tr>
<tr>
<td>Pasteur, Louis, 66</td>
<td></td>
</tr>
<tr>
<td>patch testing [hypersensitivity testing], 58</td>
<td></td>
</tr>
<tr>
<td>pathogen-associated molecular patterns (PAMPs), 26, 27</td>
<td></td>
</tr>
<tr>
<td>patient registries, 103</td>
<td></td>
</tr>
<tr>
<td>pattern-recognition receptors (PRRs), 26, 27, 74</td>
<td></td>
</tr>
<tr>
<td>pemphigus vulgaris (PV) clinical manifestations, 338</td>
<td></td>
</tr>
<tr>
<td>environmental factors, 339–40</td>
<td></td>
</tr>
<tr>
<td>epidemiology, 338</td>
<td></td>
</tr>
<tr>
<td>genetic factors, 339</td>
<td></td>
</tr>
<tr>
<td>histology, 338</td>
<td></td>
</tr>
<tr>
<td>immunohistochemistry, 338</td>
<td></td>
</tr>
<tr>
<td>infectious agents affecting, 339–40</td>
<td></td>
</tr>
<tr>
<td>pathogenesis, 339</td>
<td></td>
</tr>
<tr>
<td>vaccinations affecting, 341</td>
<td></td>
</tr>
<tr>
<td>peripheral nervous system involvement tetanus vaccination, 143</td>
<td></td>
</tr>
<tr>
<td>yellow fever vaccination, 137–8</td>
<td></td>
</tr>
<tr>
<td>pertussis vaccine autoimmune diseases induced by, 213, 284, 333</td>
<td></td>
</tr>
<tr>
<td>RA patients, 237, 240</td>
<td></td>
</tr>
<tr>
<td>phagocytic cells, alum particles taken up by, 262, 265</td>
<td></td>
</tr>
<tr>
<td>phenylmercury, 58, 59</td>
<td></td>
</tr>
<tr>
<td>plasmacytomas, induction in mice, 17, 18, 36, 37</td>
<td></td>
</tr>
<tr>
<td>platinum, allergic reaction to, 80</td>
<td></td>
</tr>
<tr>
<td>pneumococcal infections, and celiac disease, 303</td>
<td></td>
</tr>
<tr>
<td>pneumococcal vaccines, 67</td>
<td></td>
</tr>
<tr>
<td>adjuvants in, 5, 20, 191, 195, 216</td>
<td></td>
</tr>
<tr>
<td>AIRD/ARD patients, 98, 100, 109, 117, 121, 122, 193, 237, 241</td>
<td></td>
</tr>
<tr>
<td>conjugated vaccines (PCVs), 191, 192, 193, 195</td>
<td></td>
</tr>
<tr>
<td>ingredients, 5</td>
<td></td>
</tr>
<tr>
<td>polyclar acaride [nonadjuvanted] vaccines (PPVs/PSVs), 191, 192, 193, 194, 195, 238, 241</td>
<td></td>
</tr>
<tr>
<td>resultant autoimmune diseases, 193, 194, 218, 227, 323, 340, 346</td>
<td></td>
</tr>
<tr>
<td>ADEM, 323</td>
<td></td>
</tr>
<tr>
<td>bullous pemphigoid, 340</td>
<td></td>
</tr>
<tr>
<td>chronic fatigue syndrome, 346</td>
<td></td>
</tr>
<tr>
<td>Henoch–Schönlein purpura, 224</td>
<td></td>
</tr>
<tr>
<td>myositis, 351, 354</td>
<td></td>
</tr>
<tr>
<td>SLE, 218</td>
<td></td>
</tr>
<tr>
<td>safety profile, 192</td>
<td></td>
</tr>
<tr>
<td>polio vaccine, 67, 352</td>
<td></td>
</tr>
<tr>
<td>AIRD/ARD patients, 239</td>
<td></td>
</tr>
<tr>
<td>first developed, 66</td>
<td></td>
</tr>
<tr>
<td>heritability studies, 69</td>
<td></td>
</tr>
<tr>
<td>ingredients, 5</td>
<td></td>
</tr>
<tr>
<td>resultant disorders, 223, 333, 340, 340, 341, 346, 351, 352, 352</td>
<td></td>
</tr>
<tr>
<td>see also inactivated polio vaccine (IPV) polyarteritis nodosa (PAN) and HBV vaccine, 149, 154, 225 and HBV virus, 224</td>
<td></td>
</tr>
<tr>
<td>polymyalgia rheumatica (PMR), 307–9</td>
<td></td>
</tr>
<tr>
<td>and adenovirus, 18, 35</td>
<td></td>
</tr>
<tr>
<td>diagnosis, 307</td>
<td></td>
</tr>
<tr>
<td>environmental triggers, 307</td>
<td></td>
</tr>
<tr>
<td>incidence, 307</td>
<td></td>
</tr>
<tr>
<td>and influenza vaccine, 179, 225, 226</td>
<td></td>
</tr>
<tr>
<td>polyarthritis (PM), 351</td>
<td></td>
</tr>
<tr>
<td>clinical manifestations, 351</td>
<td></td>
</tr>
<tr>
<td>and HBV vaccine, 351, 352</td>
<td></td>
</tr>
<tr>
<td>and influenza vaccine, 179</td>
<td></td>
</tr>
<tr>
<td>pathogenesis, 350</td>
<td></td>
</tr>
<tr>
<td>silicone-induced, 81</td>
<td></td>
</tr>
<tr>
<td>vaccine-related cases, 351, 352</td>
<td></td>
</tr>
<tr>
<td>polynuertins, and MMR vaccine, 130</td>
<td></td>
</tr>
<tr>
<td>porcine pleuropneumonia, 38</td>
<td></td>
</tr>
<tr>
<td>post-deployment syndrome (PDS), 333</td>
<td></td>
</tr>
<tr>
<td>postural orthostatic tachycardia syndrome (POTS), and HPV vaccination, 166, 167</td>
<td></td>
</tr>
<tr>
<td>post-vaccination phenomena, as ASIA condition, 19, 79, 215, 251, 266, 276, 334</td>
<td></td>
</tr>
<tr>
<td>pregnant patients, influenza infection and vaccination, 177</td>
<td></td>
</tr>
<tr>
<td>primary ovarian failure (POF), and HPV vaccination, 166, 167</td>
<td></td>
</tr>
<tr>
<td>primate models [of adjuvant-induced autoimmunity], 37, 38–9</td>
<td></td>
</tr>
<tr>
<td>pristane, effects in animal models, 17, 36, 37, 94, 215, 234, 315</td>
<td></td>
</tr>
<tr>
<td>proinflammatory cytokines effect of alum on production of, 16</td>
<td></td>
</tr>
<tr>
<td>in pathogenesis of RA, 233–4</td>
<td></td>
</tr>
<tr>
<td>Q fever vaccine, and CPS, 333</td>
<td></td>
</tr>
<tr>
<td>QS-21 [adjuvant], 11, 12, 20</td>
<td></td>
</tr>
<tr>
<td>rabbit models [of adjuvant-induced autoimmunity], 37, 38</td>
<td></td>
</tr>
<tr>
<td>rabies vaccine</td>
<td></td>
</tr>
<tr>
<td>AIRD/ARD patients, 239</td>
<td></td>
</tr>
<tr>
<td>effects in animal models, 94</td>
<td></td>
</tr>
<tr>
<td>first developed, 66</td>
<td></td>
</tr>
<tr>
<td>ingredients, 5</td>
<td></td>
</tr>
<tr>
<td>resultant autoimmune diseases, 276, 317, 319, 323</td>
<td></td>
</tr>
</tbody>
</table>
Index
Index

systemic lupus erythematosus (SLE)  
(Continued)
long onset of autoimmunity after 
HPV vaccination, 169, 211
and MMR vaccine, 130
and pneumococcal vaccine, 194, 214
silicone-induced, 18, 35, 81, 215, 218
SLE patients 
diphtheria/tetanus/pertussis 
vaccination, 120, 213
effect of tuftsin, 13
H1N1 influenza vaccination, 181
HBV vaccination, 117–18, 211
HPV vaccination, 3, 96, 98,
109–10, 119–20, 211
influenza vaccination, 96, 98, 109,
113–16, 145, 177, 179, 181,
192
tetanus toxoid vaccination, 110,
120, 142
tuberculosis infection, 114
vaccinations (generally), 210
yellow fever vaccination, 138, 139
systemic sclerosis (SSc) 
patients, yellow fever vaccination, 138
silicone-induced, 81, 82
systems approach [to vaccine 
immunity], 66
Takayasu’s arteritis/disease, 201, 225
226
tetanus booster vaccine, resultant
autoimmune diseases, 340, 351
tetanus–diphtheria (Td) vaccine, ingredients, 5
tetanus–diphtheria–[acellular]–pertussis 
(Tdap) vaccine
AIRD/ARD patients, 110, 237
ingredients, 5
and SLE, 213
tetanus infection, 236
tetanus toxoid vaccine, 66, 67, 240, 352
adjuvant in, 19
AIRD/ARD patients, 110, 120, 121,
122, 237
autoantibody production in animal 
models, 94
heritability studies, 69
and optic neuritis, 49, 143
resultant autoimmune diseases 
ADEM, 317, 321
APS, 141–4
bullous dermatoses, 340
myositis, 351, 352
PMR, 309
TM, 49, 143
type 1 diabetes, 284
tetramethylpentadecane see pristane
thermosal [preservative]
autoimmune syndrome caused by, 2
mercury in, 58
sensitization to, 58
as vaccine ingredient, 4, 5, 178, 223,
224, 225
thrombocytopenia 
and HBV vaccine, 150, 155
and MMR vaccine, 130–1
thrombocytopenic purpura
and HPV vaccine, 165, 167
see also immune/idiopathic
thrombocytopenic purpura
tick-borne encephalitis vaccine, 239,
276
TIRAP/Mal [adapter protein], 15, 27
α-tocopherol
in H1N1 influenza vaccine, 295,
296–7
role in narcolepsy onset, 297
toll-like receptor-related adjuvants, 12,
20–1
Toll-like receptors (TLRs), 14–15, 27
adapter proteins recruited by, 15, 27
role of, 27, 74, 214
toxoid-based vaccines, 19, 66
Toxoplasma gondii infection
and bullous dermatoses, 339
and celiac disease, 303
TRAM [adapter protein], 15, 27
transverse myelitis (TM), 49, 130, 143,
152, 167, 223
diphtheria toxoid vaccine, 49
and HBV vaccine, 49, 152, 153
and HPV vaccine, 165, 167, 322
and influenza vaccine, 181, 318,
322
and MMR vaccine, 130
and polio vaccine, 223
TRIF [adapter protein], 15, 27
“Trojan horse” mechanism, 47, 266
tuberculosis vaccination against, 107, 121, 199,
200–1, 238, 242
see also BCG vaccination
ubiquitin
role in narcolepsy onset, 297
and autoimmune/inflammatory 
diseases, 226
tuberculosis infection 
AIRD/ARD patients, 107, 114, 242
and celiac disease, 303
and ITP onset, 274
tuftsin autoimmune, 13
tumor necrosis factor (TNF), 234
tumor treatments, 30
type 1 diabetes see diabetes, type 1
type 2 diabetes see diabetes, type 2
typhoid vaccine, 66
ingredients, 5
for RA patients, 239
resultant diseases, 286, 321, 346,
351, 352, 354
undefined/undifferentiated 
connective-tissue diseases 
(UCTDs), 215, 247–54
classification criteria, 247–8
comparison with ASIA, 251, 252
eriopathogenesis, 250–2
evolution to defined CTD, 249
first described, 247
resolution, 250
stability of clinical manifestations,
249, 250
uric acid, secretion of, 16
uveitis, 203
vaccination
and autoimmune disease
induction/exacerbation
[generally], 303, 309
see also autoimmune/inflammatory 
syndrome induced by adjuvants
(ASIA)
vaccine adjuvant syndrome
Gherardi’s proposal, 266
see also autoimmune/inflammatory 
syndrome induced by adjuvants
(ASIA)
Vaccine Adverse Event Reporting 
System (VAERS), 137, 164, 186,
350
analysis of reports, 130, 151, 153,
154, 155, 164, 167, 210, 241,
351, 352
“vaccine burden”, 214
“vaccine challenge”, 48
vaccine ingredients, 3, 4–5, 6
see also adjuvants
vaccine response
factors influencing, 68, 209
and genetics, 68–74
variation in individual response, 67,
68
“vaccine tattoos”, 346
vaccinia [smallpox] vaccine, 11, 25, 352
resultant autoimmune diseases, 73,
352
see also smallpox vaccine
vaccinology, history, 66–7
vaccinomics, 66, 68
varicella vaccine, 5, 66, 242
and neurological disorders, 303
RA patients, 238, 242
resultant autoimmune diseases 
ADEM, 317
and ITP, 271, 278
varicella zoster virus (VZV), 242
see also chickenpox; herpes zoster
varilisation, 25, 66
vasculitides, 223–32
nomenclature system, 223
vasculitis, post-vaccination
ANCA-associated vasculitides, 227, 228
and hepatitis A/B/C vaccines, 149,
154, 224, 225, 227, 228, 303
and HPV vaccine, 165, 167, 227
immune complex small-vessel
vasculitides, 227–8
and influenza vaccine, 98, 179, 225,
226, 227, 228
large-vessel vasculitides, 225
mechanisms, 223–5
role of adjuvants, 224–5
role of infectious agents, 223–4
medium-vessel vasculitides, 225,
227
nomenclature, 223
small-vessel vasculitides, 227
viral triggers, 1, 25, 28–9
vitamin D deficiency, as risk factor for
autoimmunity disease, 249
Index

vitamin E see α-tocopherol
vitiligo, 203, 255

water-in-oil emulsions, in adjuvants, 11, 20
Werlhof’s disease see immune/idiopathic thrombocytopenic purpura
whooping cough see pertussis
World Health Organization (WHO) on safety of vaccines, 45
on yellow fever vaccine, 136

xenobiotic adjuvants, 12–13

yeast
and celiac disease, 303
as vaccine ingredient, 4, 5, 224
yellow fever (YF), 135
clinical signs, 135
laboratory diagnosis, 135
yellow fever (YF) vaccine, 135–40
adverse events, 136–7, 139
AIRD/ARD patients, 108, 240
anaphylactic reaction to, 136
contraindications, 136
elderly patients, 136–7
first developed, 66, 136
ingredients, 5
post-vaccinal autoimmune diseases, 137–8, 286, 317, 320–1, 351, 352
protection efficacy, 136
safety, 136–7
WHO’s recommendation, 136

zoster vaccine
ingredients, 5
see also herpes zoster vaccine